High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro

被引:31
作者
Habara, K [1 ]
Ajiki, T [1 ]
Kamigaki, T [1 ]
Nakamura, T [1 ]
Kuroda, Y [1 ]
机构
[1] Kobe Univ, Sch Med, Dept Surg 1, Chuo Ku, Kobe, Hyogo 6500017, Japan
来源
JAPANESE JOURNAL OF CANCER RESEARCH | 2001年 / 92卷 / 10期
关键词
thymidylate synthase; biliary tract carcinoma; 5-fluorouracil; dihydropyrimidine dehydrogenase;
D O I
10.1111/j.1349-7006.2001.tb01068.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
To evaluate the effect of chemotherapy of 5-fluorouracil (5-FU) in human biliary tract carcinoma, we studied 5-FU sensitivity, thymidylate synthase (TS) content, and dihydropyrimidine dehydrogenase (DPD) activity in 4 human biliary tract carcinoma cell lines compared to 12 various digestive carcinoma cell lines of human organs in vitro. 5-FU sensitivity in the cell lines was analyzed by MTT assay. TS content was analyzed by the [6-H-3]FdUMP binding assay method, and DPD activity was analyzed by thin-layer chromatography (TLC). 5-FU IC50 values of biliary tract carcinoma cell lines were significantly higher than those of the carcinoma cell lines of the other digestive organs: 97, 45, 119, and 194 times the concentration of the other digestive, pancreas, colon, and gastric carcinoma cell lines, respectively. TS content of biliary tract carcinoma cell lines was also significantly greater than that of the carcinoma cell lines of the other organs. No difference in DPD activity, however, was recognized between the carcinoma cell lines of each organ. TS content in the cell lines significantly correlated with 5-FU sensitivity, but DPD activity did not. Therefore, in the present study, TS expression was concluded to influence the high resistance to 5-FU of biliary tract carcinoma in comparison with the carcinomas of the other digestive organs.
引用
收藏
页码:1127 / 1132
页数:6
相关论文
共 34 条
[1]
A ROLE FOR DIHYDROPYRIMIDINE DEHYDROGENASE AND THYMIDYLATE SYNTHASE IN TUMOR SENSITIVITY TO FLUOROURACIL [J].
BECK, A ;
ETIENNE, MC ;
CHERADAME, S ;
FISCHEL, JL ;
FORMENTO, P ;
RENEE, N ;
MILANO, G .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (10) :1517-1522
[2]
BERGER SH, 1985, MOL PHARMACOL, V28, P461
[3]
FAMILIAL DEFICIENCY OF DIHYDROPYRIMIDINE DEHYDROGENASE - BIOCHEMICAL BASIS FOR FAMILIAL PYRIMIDINEMIA AND SEVERE 5-FLUOROURACIL-INDUCED TOXICITY [J].
DIASIO, RB ;
BEAVERS, TL ;
CARPENTER, JT .
JOURNAL OF CLINICAL INVESTIGATION, 1988, 81 (01) :47-51
[4]
CLINICAL-PHARMACOLOGY OF 5-FLUOROURACIL [J].
DIASIO, RB ;
HARRIS, BE .
CLINICAL PHARMACOKINETICS, 1989, 16 (04) :215-237
[5]
RESPONSE TO FLUOROURACIL THERAPY IN CANCER-PATIENTS - THE ROLE OF TUMORAL DIHYDROPYRIMIDINE DEHYDROGENASE-ACTIVITY [J].
ETIENNE, MC ;
CHERADAME, S ;
FISCHEL, JL ;
FORMENTO, P ;
DASSONVILLE, O ;
RENEE, N ;
SCHNEIDER, M ;
THYSS, A ;
DEMARD, F ;
MILANO, G .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (07) :1663-1670
[6]
HARRIS BE, 1990, CANCER RES, V50, P197
[7]
5-FLUOROURACIL, MITOMYCIN, AND DOXORUBICIN (FAM) IN CARCINOMA OF THE BILIARY-TRACT [J].
HARVEY, JH ;
SMITH, FP ;
SCHEIN, PS .
JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (11) :1245-1248
[8]
HEGGIE GD, 1987, CANCER RES, V47, P2203
[9]
FLUORINATED PYRIMIDINES, A NEW CLASS OF TUMOUR-INHIBITORY COMPOUNDS [J].
HEIDELBERGER, C ;
CHAUDHURI, NK ;
DANNEBERG, P ;
MOOREN, D ;
GRIESBACH, L ;
DUSCHINSKY, R ;
SCHNITZER, RJ ;
PLEVEN, E ;
SCHEINER, J .
NATURE, 1957, 179 (4561) :663-666
[10]
Homma S, 1988, Hum Cell, V1, P95